| scholarly article | Q13442814 |
| P356 | DOI | 10.1586/EGH.10.22 |
| P698 | PubMed publication ID | 20528116 |
| P2093 | author name string | Peter D R Higgins | |
| Ryan W Stidham | |||
| P2860 | cites work | European evidence based consensus on the diagnosis and management of Crohn's disease: special situations | Q22242050 |
| Role of US in detection of Crohn disease: meta-analysis | Q33218213 | ||
| Autoantibodies against ubiquitination factor E4A (UBE4A) are associated with severity of Crohn's disease | Q33309442 | ||
| Role of faecal calprotectin as non-invasive marker of intestinal inflammation. | Q34270506 | ||
| Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease | Q34792495 | ||
| Cytokine gene polymorphism in human disease: on-line databases, supplement 2. | Q34810493 | ||
| Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease | Q36207252 | ||
| Monocyte-conditioned medium, interleukin-1, and tumor necrosis factor stimulate the acute phase response in human hepatoma cells in vitro | Q36215278 | ||
| The immune response in inflammatory bowel disease | Q36846736 | ||
| Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults | Q37035957 | ||
| The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up. | Q37365418 | ||
| Monitoring disease activity by stool analyses: from occult blood to molecular markers of intestinal inflammation and damage | Q37366272 | ||
| Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease. | Q37442760 | ||
| Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort | Q40186159 | ||
| Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease | Q41609900 | ||
| Practice parameters for the treatment of mucosal ulcerative colitis--supporting documentation. The Standards Practice Task Force. The American Society of Colon and Rectal Surgeons | Q41642709 | ||
| Long-term evolution of disease behavior of Crohn's disease | Q44444450 | ||
| Endoscopy and MR enteroclysis: equivalent tools in predicting clinical recurrence in patients with Crohn's disease after ileocolic resection | Q44538984 | ||
| Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality | Q44911874 | ||
| Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease | Q45181649 | ||
| Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. | Q45892140 | ||
| Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis. | Q45926125 | ||
| Anti-flagellin (CBir1) phenotypic and genetic Crohn's disease associations. | Q45983344 | ||
| Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse | Q50615769 | ||
| Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine | Q51044192 | ||
| Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. | Q51739537 | ||
| Magnetic resonance colonography for the evaluation of colonic inflammatory bowel disease: correlation with conventional colonoscopy. | Q51852485 | ||
| Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. | Q51868985 | ||
| Sustained improvement of health-related quality of life in Crohn's disease patients treated with infliximab and azathioprine for 4 years. | Q53188371 | ||
| Multi-detector CT-colonography in inflammatory bowel disease: prospective analysis of CT-findings to high-resolution video colonoscopy. | Q53560632 | ||
| Risk factors for opportunistic infections in patients with inflammatory bowel disease. | Q53974675 | ||
| CRP correlates with clinical score in ulcerative colitis but not in Crohn's disease. | Q54386421 | ||
| Seroreactivity to microbial components in Crohn's disease is associated with ileal involvement, noninflammatory disease behavior and NOD2/CARD15 genotype, but not with risk for surgery in a Hungarian cohort of IBD patients. | Q54443565 | ||
| Human CRP Gene Polymorphism Influences CRP Levels | Q57243067 | ||
| Fecal calprotectin remains high during glucocorticoid therapy in children with inflammatory bowel disease | Q57675111 | ||
| P433 | issue | 3 | |
| P921 | main subject | biomarker | Q864574 |
| inflammatory bowel diseases | Q917447 | ||
| P304 | page(s) | 285-291 | |
| P577 | publication date | 2010-06-01 | |
| P1433 | published in | Expert Review of Gastroenterology & Hepatology | Q15733730 |
| P1476 | title | Value of mucosal assessment and biomarkers in inflammatory bowel disease | |
| P478 | volume | 4 |
| Q35840853 | Biomarkers in inflammatory bowel disease: current practices and recent advances |
| Q43873083 | Evaluation of responsive gene expression as a sensitive and specific biomarker in patients with ulcerative colitis |
| Q38918650 | Fecal biomarkers in inflammatory bowel disease: how, when and why? |
| Q43240077 | Histological healing in inflammatory bowel disease: a still unfulfilled promise |
| Q36125752 | Immune markers and differential signaling networks in ulcerative colitis and Crohn's disease |
| Q27025063 | Indoleamine 2,3 dioxygenase in intestinal disease |
| Q38005972 | Mucosal healing in Crohn's disease: a systematic review |
| Q44207443 | Normalization of mucosal cytokine gene expression levels predicts long-term remission after discontinuation of anti-TNF therapy in Crohn's disease |
| Q53427009 | Remission maintained by monotherapy after biological + immunosuppressive combination for Crohn's disease in clinical practice. |
| Q35679307 | The current and future role of endomicroscopy in the management of inflammatory bowel disease. |
| Q47692659 | Usefulness of Transcriptional Blood Biomarkers as a Non-invasive Surrogate Marker of Mucosal Healing and Endoscopic Response in Ulcerative Colitis |
Search more.